Related Experiment Video

Updated: Jul 14, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.1K

Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β

Steve Simpson-Yap1, Ashkan Pirmani2, Edward De Brouwer3

  • 1CORe, Department of Medicine, The University of Melbourne, Australia; Neuroepidemiology Unit, Melbourne School of Population & Global Health, The University of Melbourne, Australia; Menzies Institute for Medical Research, University of Tasmania, Australia.

Multiple Sclerosis and Related Disorders
|August 2, 2022
PubMed
Abstract

Insights

Interferon-beta (IFNβ) treatment for multiple sclerosis (MS) showed a milder COVID-19 course compared to no treatment. However, IFNβ did not reduce COVID-19 severity compared to other disease-modifying therapies (DMTs).

Area of Science:

  • Neurology
  • Immunology
  • Infectious Diseases

Background:

  • Multiple sclerosis (MS) patients often use disease-modifying therapies (DMTs).
  • Investigating the impact of DMTs on COVID-19 severity in MS is crucial.
  • Interferon-beta (IFNβ) is a common DMT for MS.

Discussion:

  • This study compared COVID-19 severity in MS patients on IFNβ versus untreated patients and those on other DMTs.
  • Results indicate IFNβ was associated with less severe COVID-19 than no treatment.
  • No significant difference in COVID-19 severity was observed between IFNβ and glatiramer acetate, dimethyl fumarate, or other pooled DMTs.

Key Insights:

  • Interferon-beta (IFNβ) treatment in multiple sclerosis (MS) patients was linked to a milder COVID-19 outcome compared to untreated individuals.
  • No protective effect of IFNβ against severe COVID-19 was found when compared to other common MS DMTs.
  • The findings do not support using IFNβ specifically to mitigate COVID-19 severity in MS patients.

Outlook:

  • Further research may explore differential impacts of various DMTs on viral infections.
  • Understanding drug interactions between DMTs and antiviral treatments is warranted.
  • Clinical decisions regarding DMTs should prioritize MS management over COVID-19 prevention based on current data.

More Related Videos

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.5K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.4K

Related Concept Videos

Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...